Pharma antitrust dispute ‘must be arbitrated’, says US court
A US appeals court has upheld its ruling that an antitrust class action against US pharmaceutical conglomerate Johnson & Johnson over an alleged anticompetitive scheme to protect billion-dollar sales of an autoimmune drug must be arbitrated.
To read more
Subscribe to Global Arbitration Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Arbitration Review experts.